In a report released today, Yun Zhong from Wedbush reiterated a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of $18.00.
Yun Zhong has given his Buy rating due to a combination of factors that highlight Wave Life Sciences’ potential for significant growth. The anticipated clinical data from their AATD and obesity programs in the second half of 2025 are expected to act as strong catalysts for the company’s stock. Despite recent concerns about the FDA’s accelerated approval pathway changes, Wave Life Sciences has shown promising functional data for their DMD and HD programs, which supports the clinical benefit of their treatments.
Furthermore, the company’s financial position is solid, with a cash runway extending into 2027, providing stability as they prepare for important clinical updates. The upcoming data releases, particularly the repeat dosing data for WVE-006 and initial data for WVE-007, are expected to demonstrate significant advancements in their therapeutic programs. These developments, alongside strategic partnerships and ongoing preparations for regulatory submissions, reinforce the positive outlook for Wave Life Sciences, making the current share price a potentially attractive entry point for investors.
Zhong covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Voyager Therapeutics, and Ascendis Pharma. According to TipRanks, Zhong has an average return of -19.3% and a 32.29% success rate on recommended stocks.
In another report released on May 5, Leerink Partners also reiterated a Buy rating on the stock with a $24.00 price target.